Building cell therapy leadership in EuropeIn these videos, Markwin Velders and Louis van de Wiel of Kite, a Gilead Company, provide a behind Share XBuilding cell therapy leadership in Europehttps://pharmaphorum.com/video/building-cell-therapy-leadership-europe/
AstraZeneca and lung cancer: the pharmaphorum podcastThis episode of the pharmaphorum podcast focuses on lung cancer, with AstraZeneca’s VP, global franchise head, Tagrisso TDR Share XAstraZeneca and lung cancer: the pharmaphorum podcasthttps://pharmaphorum.com/podcast/astrazeneca-and-lung-cancer
Lung cancer’s patient information gap: the pharmaphorum podcastFor episode 13 of the pharmaphorum podcast podcast I went to AstraZeneca’s London base to meet Paul Naish, Share XLung cancer’s patient information gap: the pharmaphorum podcasthttps://pharmaphorum.com/podcast/lung-cancers-patient-information-gap
ASCO 2019 – Kantar considers MacroGenics’ phase 3 SOPHIA trialKantar analyst Katie Stockstill discusses the results of phase 3 SOPHIA trial that were presented on the last Share XASCO 2019 – Kantar considers MacroGenics’ phase 3 SOPHIA trialhttps://pharmaphorum.com/spotlight/asco-2019-and-the-future-of-oncology/kantar-macrogenics-phase-3-sophia-trial/
ASCO 2019 – phase I data generates hope for the futureSometimes interesting stories from the ASCO conference are the phase I data that generates hope for the future. Share XASCO 2019 – phase I data generates hope for the futurehttps://pharmaphorum.com/spotlight/asco-2019-and-the-future-of-oncology/amgen-kras-amg510-phase-i-data/
ASCO 2019 – Enfortumab comes out fighting in bladder cancerAt ASCO 2019, results were presented from the phase II EV-201 trial, which evaluated antibody drug conjugate (ADC) Share XASCO 2019 – Enfortumab comes out fighting in bladder cancerhttps://pharmaphorum.com/video/asco-2019-enfortumab-bladder-cancer/
ASCO 2019 – Kantar highlights a selection of exciting Phase I and Phase II resultsAt ASCO, a lot of attention is given to the results of the large, clinical practices changing phase Share XASCO 2019 – Kantar highlights a selection of exciting Phase I and Phase II resultshttps://pharmaphorum.com/video/asco-2019-results-clinical-practices-changing-phase-iii-studies/
ASCO 2019 – Kantar debates results from the KEYNOTE-062 trialThere were a number of debate-worthy outcomes from the KEYNOTE-062 trial that was presented at ASCO 2019 in Share XASCO 2019 – Kantar debates results from the KEYNOTE-062 trialhttps://pharmaphorum.com/spotlight/asco-2019-and-the-future-of-oncology/asco-2019-kantar-debate-results-from-keynote-062-trial/
ASCO 2019 – Kantar reviews results from phase 3 POLO trialLynparza is paving new ground in pancreatic cancer, aiming to establish a maintenance setting and patient segmentation based Share XASCO 2019 – Kantar reviews results from phase 3 POLO trialhttps://pharmaphorum.com/spotlight/asco-2019-and-the-future-of-oncology/asco-2019-kantar-phase-3-polo-trial/
